Abstract
BackgroundImmune checkpoint inhibitors (ICIs) have been used to treat many distinct cancers, including non-small cell lung cancer (NSCLC). Better tools are needed to predict which patients will benefit from ICI...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
